Mesothelioma Research, COVID Findings Featured at IASLC Conference

This study, performed during the pre-vaccine period of the pandemic, once again demonstrates the importance of vaccination against COVID-19,” said Dr. Susana Cedres, a medical oncologist with Vall d’Hebron Hospital. “Malignant pleural mesothelioma patients are particularly vulnerable to COVID-19.” Cedres said since the subsequent rollout of the COVID-19 vaccines, no positive cases have been attributed to pleural mesothelioma patients at the hospital. The average age of the seven patients was 62. All had the epithelioid histology of mesothelioma and two were receiving oncologic treatment at the time of diagnosis. Median overall survival of the seven was 17.8 months from the time of their cancer diagnosis, but less than two weeks from the COVID diagnosis. “If a patient with this particular disease is diagnosed with the virus, he or she is at increased risk of mortality,” Cedres said. “Infection must therefore be prevented, and we know that the vaccine works.” Second-Line Mesothelioma Treatment Has Potential The virtual World Conference on Lung Cancer included other mesothelioma presentations, particularly on treatment advances. In one phase II multicenter study in Europe, heavily pretreated mesothelioma patients found promise with the drug lurbinectedin. Both lung cancer and mesothelioma cancer patients showed clear clinical benefits from the anti-tumor, synthetically produced agent. The 55 mesothelioma pat...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

"I think the biggest challenge for the health care field in the next decade will be determining the next course of action in the face of the gaps exposed throughout the pandemic," Mona Veiseh said.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
The $500 million project targets mRNA vaccines for COVID-19 and other viral infections
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
"I think the biggest challenge for the health care field in the next decade will be determining the next course of action in the face of the gaps exposed throughout the pandemic," Mona Veiseh said.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
When it comes to malignant pleural mesothelioma, not everyone is treated equally. A disparity in access to care makes the difference in mesothelioma treatment quite dramatic, according to the University of Miami’s Sylvester Comprehensive Cancer Center. “Patients without access to expert multidisciplinary care at high-volume, academic facilities are being inappropriately undertreated for their disease,” medical oncologist Dr. Estelamari Rodriguez told The Mesothelioma Center at Asbestos.com. “The access is not adequate as it should be for everyone.” Rodriguez led a recent study at Univers...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Mesothelioma Source Type: research
The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the immunotherapy drug durvalumab. FDA approval may be coming soon. “It looks very promising,” Dr. Arkadiusz Dudek, of Regions Hospital Cancer Care Center in St. Paul, Minnesota, told The Mesothelioma Center at Asbestos.com. “The hope is to have the regimen approved by the FDA as front-line therapy. There is a real need today for more options with mesothelioma.” The goal of the randomized trial – officially known as DREAM3R &...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Urgent referrals for cancer in general and for lung cancer specifically have fallen during the COVID-19 pandemic that will likely lead to an increase in mortality and morbidity from lung cancer. The appendix reproduces a submission by the Clinical Expert Group for lung cancer and mesothelioma which includes recommendations about differentiation of symptoms from lung cancer from those due to COVID-19 and recommendations for easy access of patients with concerning symptoms for assessment by primary care.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
The COVID-19 pandemic closed educational institutions everywhere, but it also opened a door to the acceleration of vitally important asbestos abatement in schools where children would have been in attendance. Business has been booming. “It does look like a lot of schools took advantage of it [the closing of facilities],” Brent Kynoch, managing director of the Environmental Information Association, told The Mesothelioma Center at Asbestos.com. “They may have had work contracted for later in the summer, but just said, ‘Let’s get started with it now, and get it done.’ They understood the im...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Doctors, scientists and occupational health experts from across the country are openly criticizing the U.S. Environmental Protection Agency’s recent asbestos draft risk evaluation. At a virtual press conference arranged by the Asbestos Disease Awareness Organization last week, speakers labeled the asbestos evaluation inadequate and in need of serious revision. The year-long evaluation was required as part of the Frank R. Lautenberg Chemical Safety for the 21st Century Act, which was passed in 2016. It amended the original Toxic Substances Control Act, the country’s primary chemicals management law. “I am...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Johnson &Johnson announced Tuesday that it will stop selling its iconic, talc-based baby powder, the target of thousands of lawsuits claiming that its talc was contaminated with asbestos, which led to cancers such as mesothelioma and ovarian cancer. The company said the stoppage is only in the United States and Canada, citing a decline in consumer demand and “misinformation” about the safety of the product. “Demand for talc-based Johnson’s Baby Powder in North America has been declining due in large part to changes in consumer habits and fueled by misinformation around the safety of the product ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiovascular & Thoracic Surgery | Chemotherapy | Conferences | COVID-19 | Databases & Libraries | Environmental Health | Food and Drug Administration (FDA) | Hospitals | Immunotherapy | Lung Cancer | Mesothelioma | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Netherlands Health | Pandemics | Pneomococcal Vaccine | Spain Health | Study | Switzerland Health | Texas University | Vaccines | Yervoy